{"description":"Population for All-cause mortality included all enrolled participants. Population for Non-serious adverse events and serious adverse events included all participants that received at least 1 vaccination with 9vHPV vaccine and provided safety data at any time during the study.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":201,"description":"Participants received a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6","id":"EG000","otherNumAffected":90,"otherNumAtRisk":200,"seriousNumAffected":1,"seriousNumAtRisk":200,"title":"9vHPV Vaccine"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","stats":[{"groupId":"EG000","numAffected":89,"numAtRisk":200,"numEvents":138}],"term":"Injection site pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.1","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":200,"numEvents":16}],"term":"Injection site swelling"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":200,"numEvents":1}],"term":"Subcutaneous abscess"}],"timeFrame":"Up to 4 weeks postdose 3 (Month 7)"}